Several pilot studies have been conducted in Japan to determine the efficacy and safety of SGLT-2 inhibitors for patients with type 2 diabetes and NAFLD or NASH (74–77). The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.